menu search

ETNB / TEVA Beats Q4 Earnings Estimates, Sales Miss & Stock Down

TEVA Beats Q4 Earnings Estimates, Sales Miss & Stock Down
TEVA reports mixed Q4 results, beating earnings estimates, while sales slightly miss estimates. Stock down post earnings release. Read More
Posted: Feb 9 2023, 09:48
Author Name: Zacks Investment Research
Views: 111935

ETNB News  

89bio's Low Price Presents An Opportunity

By Seeking Alpha
October 26, 2023

89bio's Low Price Presents An Opportunity

89bio, Inc. stock dropped along with other NASH players after Akero's efruxifermin failed a phase 2 trial. Despite the drop, 89bio remains attractive more_horizontal

89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference

By GlobeNewsWire
October 17, 2023

89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference

SAN FRANCISCO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and more_horizontal

Why Shares of 89bio Plummeted on Tuesday

By The Motley Fool
October 10, 2023

Why Shares of 89bio Plummeted on Tuesday

89bio is a clinical-stage biotech company. It focuses on treatments for liver and cardiometabolic diseases. more_horizontal

89bio earns ‘Buy' rating in initial coverage on positive prospects for NASH therapeutic

By Proactive Investors
August 28, 2023

89bio earns ‘Buy' rating in initial coverage on positive prospects for NASH therapeutic

Analysts at UBS have initiated coverage on 89bio (ETNB) with a ‘Buy' rating and a US$36 price target, representing an upside of about 117.5% from th more_horizontal

89bio, Inc.: A Big Bet On NASH

By Seeking Alpha
August 10, 2023

89bio, Inc.: A Big Bet On NASH

89bio, Inc. is a clinical-stage biotech company focused on developing therapies for liver and cardio-metabolic diseases. The stock surged after top-li more_horizontal

89bio shares rise as analysts see improved outlook for NASH treatments

By Market Watch
June 13, 2023

89bio shares rise as analysts see improved outlook for NASH treatments

Shares of clinical-stage biopharma company 89bio Inc. ETNB, +4.38% gained 4.8% premarket on Tuesday as Evercore ISI analysts initiated coverage of the more_horizontal

89BIO (ETNB) Just Overtook the 20-Day Moving Average

By Zacks Investment Research
May 29, 2023

89BIO (ETNB) Just Overtook the 20-Day Moving Average

89BIO (ETNB) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ETNB crossed a more_horizontal

89bio: Great Prospects After Excellent Phase 2 Data

By Seeking Alpha
May 28, 2023

89bio: Great Prospects After Excellent Phase 2 Data

ETNB posted excellent phase 2 data in March. They plan to start a phase 3 trial now. more_horizontal


Search within

Pages Search Results: